Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load

Journal of Clinical Virology

Volumn 50, Issue 1, 2011, Pages 13-18

  De Souza, Jaqueline Gontijo ^a,d   Da Fonseca, Flávio Guimarães ^a   Martins, Marina Lobato ^b,d   Martins, Camila Pacheco Silveira ^a,d   De Carvalho, Luciana Debortoli ^a,d   Coelho dos Reis, Jordana Grazziela Alves ^a,d   Carneiro Proietti, Anna Bárbara Freitas ^b,d   Martins Filho, Olindo Assis ^c,d   Barbosa Stancioli, Edel Figueiredo ^a,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FUNDAÇÃO HEMOMINAS   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d Interdisciplinary HTLV Research Group   (Brazil)

Author keywords

HAM TSP; HTLV 1; Rheumatologic diseases; Tax

Indexed keywords

IMMUNOGLOBULIN G; TAX ANTIBODY; TAX PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; FEMALE; FLOW CYTOMETRY; HTLV 1 ASSOCIATED MYELOPATHY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATIC DISEASE; SERODIAGNOSIS; TROPICAL SPASTIC PARAPARESIS; VACCINIA VIRUS; VIRUS CARRIER; VIRUS LOAD;

ANTIBODIES, VIRAL; CARRIER STATE; CELL CULTURE TECHNIQUES; FEMALE; GENE PRODUCTS, TAX; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOGLOBULIN G; MALE; PARAPARESIS, TROPICAL SPASTIC; PROVIRUSES; VIRAL LOAD;

EID: 78650953060     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.09.007     Document Type: Article

References (30)

1. Manns A., Hisada M., Grenade L.L. Human T-lymphotropic virus type I infection. Lancet 1999, 353:1951-1958.
2. De The G., Bomford R. An HTLV-I vaccine: why, how, for whom?. AIDS Res Hum Retroviruses 1993, 9(5):381-386.
3. Edlich R.F., Arnette J.A., Willians F.M. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 2000, 18(1):109-119.
4. Murphy E.L., Figueiroa J.P., Gibbs W.N., Holding-Cobham M., Cranston B., Malley K., et al. Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants. Am J Epidemiol 1991, 133(11):1114-1124.
5. Mathieux R., Horal P., Mauclere P., Mercereau-Puijalon O., Guillotte M., Meertens L., et al. Human T-cell lymphotropic virus type 1 Gag indeterminate Western blot patterns in Central Africa: relationship to Plasmodium falciparum infection. J Clin Microbiol 2000, 38(11):4049-4057.
6. Rouet F., Meertens L., Courouble G., Herrmann-Storck C., Pabingui R., Chancerel B., et al. Serological, epidemiological, and molecular differences between human T-cell lymphotropic virus type 1 (HTLV-1)-seropositive healthy carriers and persons with HTLV-1 Gag indeterminate western blot patterns from the Caribbean. J Clin Microbiol 2001, 39(4):1247-1253.
7. Carneiro-Proietti A.B.F., Catalan-Soares B., Proietti F.A. Human T cell lymphotropic viruses (HTLV-I/II) in South America: should it be a public health concern?. J Biomed Sci 2002, 9:587-595. GIPH.
8. Kazanji M., Gessain A. Human T-cell lymphotropic virus types I and II (HTLV-I/II) in French Guiana: clinical and molecular epidemiology. Cad Saúde Pública 2003, 19(5):1227-1240.
9. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-Cell leukemia: clinical and hematologic features of 16 cases. Blood 1977, 50(3):481-492.
10. Mochizuki M., Ono A., Ikeda E., Hikita N., Watanabe T., Yamaguchi K., et al. HTLV-I uveitis. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13(1):50-56.
11. Osame, Mitsuhiro The past, the present and the future of HAM/TSP research. J Acquir Immune Defic Syndr 1999, 20(4):pA22.
12. Cruz B.A., Catalan-Soares B., Proietti F. Manifestações Reumáticas associadas ao Vírus Linfotrópico Humano de Células T do Tipo I (HTLV-I). Rev Bras Reumatol 2005, 45(2):71-77.
13. Boxus M., Twizere J.C., Legros S., Dewulf J.F., Kettmann J., Willems L. The HTLV-I Tax interactome. Retrovirology 2008, 5:76.
14. Perkins N.D. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62.
15. Royer-Leveau C., Mordelet E., Delebecque F., Gessain A., Charneau P., Ozden S. Efficient transfer of HTLV-1 tax gene in various primary and immortalized cells using a flap lentiviral vector. J Virol Methods 2002, 105(1):133-140.
16. Earl P.L., Koenig S., Moss B. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J Virol 1991, 65(1):31-41.
17. Souza J.G., Fonseca F.G., Martins-Filho O.A., Teixeira-Carvalho A., Martins C.P.S., Carvalho L.D., et al. Diagnostic tool based on an HTLV-1 Tax expression system in eukaryotic cells using a poxvirus vector. J Virol Methods 2010, 166:65-71.
18. Jacobson S., Shida H., Mcfarlin D.E., Fauci A.S., Koening S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 1990, 348:245-248.
19. Levin M.C., Lee S.M., Kalume F., Morcos Y., Dohan F.C., Hasty K.A., et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 2002, 8(5):455-457.
20. Noraz N., Benichous S., Madaule P., Tiollais P., Vernant J.C., Desgranges C. Expression of HTLV-I Env and tax recombinant peptides in yeast: identification of immunogenic domains. Virology 1993, 193:80-88.
21. Burbelo P.D., Meoli E., Leahy H.P., Graham J., Yao K., Oh U., et al. Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 2008, 5(96):1-11.
22. Lal R.B., Giam C.Z., Coligan J.E., Rudolph D.L. Differential immune responsiveness to the immunodominant epitopes of regulatory proteins (tax and rex) in human T cell lymphotropic virus type I-associated myelopathy. J Infect Dis 1994, 169(3):496-503.
23. Bangham Charles R.M. The immune response to HTLV-I. Curr Opin Immunol 2000, 12:397-402.
24. Wodarz D., Hall S., Usuku K., Osame M., Ogg G.S., Mcmichael A.J., et al. Cytotoxic T-cell abundance immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. Proc R Soc Lond B Biol Sci 2001, 268:1215-1221.
25. Jacobson Steven Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis 2002, 186(2):187-192.
26. Asquith B., Mosley A., Barfield A., Marshall S., Goon P., Hanon E., et al. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol 2005, 86:1515-1523.
27. Kubota R., Kawanishi T., Matsubara H., Manns A., Jacobson S. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol 1998, 161:482-488.
28. Kubota R., Fujiyoshi T., Izumo S., Yahiki S., Maruyama I., Osame M., et al. Fluctuation of HTLV-I proviral DNA in peripheral blood mononuclear cells of HTLV-I-associated myelopathy. J Neuroimmunol 1993, 42:147-154.
29. Best I., Adaui V., Verdonck E.G., Tipismana M., Clarck D., Gotuzzo E., et al. Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol 2006, 146:226-233.
30. Yakova M., Lézin A., Dantini F., Lagathu G., Olindo S., Jean-Baptiste G., et al. Increased proviral load in HTLV-I-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005, 2:4-13.